Raloxifene: risks and benefits.
Raloxifene, a selective estrogen receptor modulator (SERM), was designed to have the expected benefits of long-term estrogen replacement therapy without the risks. This paper reviews the clinical trial evidence for raloxifene benefits and risks, and how they compare with those of hormone replacement therapy (HRT) and relate to the choices of postmenopausal women.
Barrett-Connor
E
E
Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093, USA. ebarrettconnor@ucsd.edu
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004717:Endometrium / Q000187:drug effects; D005260:Female; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D009017:Morbidity; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D013923:Thromboembolism / Q000139:chemically induced
D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride